A Single Dose of SARS-CoV-2 Vaccine Primes a Strong Humoral Immune Response in COVID-19–Recovered Patients
| Autor: | Mohammad A Alsarani, Waleed H. Mahallawi, Rami H Aljohani, Nadir A. Ibrahim, Salah A Al-Mutabgani, Mohamed H Fakher |
|---|---|
| Rok vydání: | 2022 |
| Předmět: |
Male
COVID-19 Vaccines Coronavirus disease 2019 (COVID-19) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Immunology Virus Vaccine administration Immune system ChAdOx1 nCoV-19 Virology Humans Medicine BNT162 Vaccine biology SARS-CoV-2 business.industry COVID-19 Serum samples Immunity Humoral Antibody response Immunoglobulin G biology.protein Molecular Medicine Female Antibody business |
| Zdroj: | Viral Immunology. 35:122-128 |
| ISSN: | 1557-8976 0882-8245 |
| DOI: | 10.1089/vim.2021.0108 |
| Popis: | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection causes coronavirus disease 2019 (COVID-19), which has affected hundreds of millions of people globally. The development of safe and effective vaccines represents an urgent demand. A total of 136 participants were recruited in this study, including 75 men and 61 women. The participants were divided into two groups: those who were virus naïve (never infected) and those who had recovered from COVID-19. Each group included individuals who received either the Pfizer-BioNTech BNT162b2 mRNA or the Oxford-AstraZeneca ChAdOx1 COVID-19 vaccine. Enzyme-linked immunosorbent assay (ELISA) was used to measure anti-S IgG antibody concentrations in sequential serum samples obtained before vaccine administration, after the first vaccine dose, and after the second vaccine dose. We compared the antibody responses of individuals with confirmed prior COVID-19 infection with those of individuals without prior evidence of infection. All participants who were previously infected with SARS-CoV-2 who received one dose of either the Pfizer-BioNTech BNT162b2 mRNA or the Oxford-AstraZeneca ChAdOx1 COVID-19 vaccine showed significant anti-S IgG antibody levels. No sex-related differences were observed when we compared antibody levels between men and women. In infection-naïve participants ≥60 years, a second vaccine dose was necessary to achieve higher levels of antibody when comparing the IgG antibody levels after receiving the first and second dose. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|